Medley (4480) Fundamentals 2026 — P/E 67.3x, Revenue Analysis | SniperIQ
Medley (4480) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥62.6B, trading at ¥2082.00 on the JPX. This SniperIQ fundamentals page covers Medley's valuation (P/E 67.3x, P/B 4.8x), profitability (net margin 2.5%), revenue (¥36.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Medley's market cap?
Medley (4480) has a market capitalization of approximately ¥62.6B, trading at ¥2082.00 on the JPX. Market cap moves with the live share price.
What is Medley's P/E ratio?
Medley's trailing twelve-month P/E ratio is 67.3x, with a price-to-book (P/B) of 4.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Medley?
Medley runs a net profit margin of 2.5%, a gross margin of 61.7%, and an operating margin of 5.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Medley generate?
Medley reported revenue of ¥36.8B for fiscal year 2025, with net income of ¥975M and earnings per share (EPS) of 30.6. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Medley pay a dividend?
Medley does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Medley financially healthy?
Medley carries a debt-to-equity ratio of 1.53x and a current ratio of 1.36x, with a market beta of 0.77. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Medley a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medley (4480) the key facts are: market cap ¥62.6B, P/E 67.3x, revenue ¥36.8B, 52-week range 1715-3260. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Medley's full fundamentals live
Get Medley's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.